It's possible, but PAR will need to deliver on their promises first, which is unlikely if past precedent is anything to go by. If PAR deliver on partnerships and apply for accelerated approval, then sure we will trend in the same manner as NEU. But why would they when they have an endless supply of free/cheap money with no accountability?
NEU and TLX are prime examples of how biopharma companies should be run.
Chart, page-3431
-
- There are more pages in this discussion • 852 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $76.95M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 23.5¢ | 22.0¢ | $66.95K | 294.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 90092 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 25858 | 1 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |